Sederma
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
8
Ending by 2030
Aug 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 9 to 27, 2026 · next Dec 9
- 1 fee due Jan 2, 2027The maintenance fee for Topical cosmetic treatment of skin and scalp and corresponding active ingredient based on an extract of Apium graveolens (US 10,335,354) comes due Jan 2, 2027. Unpaid by Jul 2, 2027, it lapses early.
- 1 fee due Mar 8, 2027The maintenance fee for Cosmetic use of geranylgeranyl-2-propanol (US 9,126,060) comes due Mar 8, 2027. Unpaid by Sep 8, 2027, it lapses early.
- 1 fee due May 28, 2027The maintenance fee for Synthesis strategy for gap protecting group (US 11,827,660) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,998,493 | Cosmetic or dermopharmaceutical compositions which are used to reduce bags and circles under the eyes In force · From the USPTO record | In force | From the USPTO record | |
| US 8,530,426 | Cosmetic or dermopharmaceutical composition comprising at least one UDP glucuronosyl transferase (UGT) enzymes inducer In force · From the USPTO record | In force | From the USPTO record | |
| US 8,404,648 | Polypeptides KXK and their use In force · From the USPTO record | In force | From the USPTO record | |
| US 8,846,019 | Use of protoberberines as an active substance regulating the pilosebaceous unit In force · From the USPTO record | In force | From the USPTO record | |
| US 8,361,516 | Composition comprising sarsasapogenin In force · From the USPTO record | In force | From the USPTO record | |
| US 8,697,656 | Compounds, in particular peptides, compositions comprising them and cosmetic and dermo-pharmaceutical uses In force · From the USPTO record | In force | From the USPTO record | |
| US 8,741,357 | Cosmetic or dermopharmaceutical composition comprising an euglena extract In force · From the USPTO record | In force | From the USPTO record | |
| US 9,050,477 | Cosmetic compositions comprising oridonin and new cosmetic uses In force · From the USPTO record | In force | From the USPTO record | |
| US 10,159,636 | Cosmetic composition containing acetylated oligoglucuronans In force · From the USPTO record | In force | From the USPTO record | |
| US 9,126,060 | Cosmetic use of geranylgeranyl-2-propanol In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 29: 2 lapsed for an unpaid fee · 6 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 1 abandoned · 10 no status recorded